The Economic Case for Automation & GenAI in Life Sciences R&D: Converting Potential
An ArisGlobal best practice guide, informed by investor insight from Nordic Capital
Gain the Decision Advantage
Breakthrough 2027 brings together life sciences leaders, industry regulators and experts, to explore the future of AI in life sciences.
An ArisGlobal best practice guide, informed by investor insight from Nordic Capital
Embed the latest GenAI and LLM-powered technologies powered by LifeSphere NavaXâ„¢ across the end-to-end Regulatory lifecycle.
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2026 ArisGlobal – All Rights Reserved